Results 31 to 40 of about 3,573 (200)
Identification of predictors of response to Erenumab in a cohort of patients with migraine
Cephalalgia Reports, 2021 Background: The migraine-specific monoclonal antibody Erenumab targeting the calcitonin gene related peptide receptor is an effective and well tolerated preventive treatment of episodic and chronic migraine.
Houssein Salem-Abdou +2 more
doaj +1 more source
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options : A Literature Review [PDF]
, 2023 Chronic pain conditions have a high socio-economic impact and represent a burden for patients, and their management is a challenge for healthcare professionals.
Csáti Anett +3 more
core +1 more source
A Comparison of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard Migraine Prophylaxis in Those with Episodic Migraines [PDF]
, 2023 Migraines are debilitating and a frequent reason for primary care visits. Migraines interfere with an individual’s work, school, and daily life.
Harms, Alexie
core +4 more sources
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment [PDF]
, 2023 : The introduction of monoclonal antibodies (mAbs) directed against the calcitonin gene-related peptide (CGRP), or its receptor (CGRPr), revolutionized migraine management due to their high efficacy and few side effects.
Alonge, Paolo +12 more
core +1 more source
Efficacy and safety of erenumab in women with a history of menstrual migraine
The Journal of Headache and Pain, 2020 Background We performed a post hoc, subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled study of erenumab for prevention of episodic migraine (STRIVE) to determine the efficacy and safety of erenumab in women with self-reported ...
Jelena M. Pavlovic +8 more
doaj +1 more source
Clinical practice in prevention of migraine with calcitonin-gene related peptide monoclonal antibodies: real-world evidence [PDF]
, 2022 Introducción: Los anticuerpos monoclonales (mAbs) del péptido relacionado con el gen de la calcitonina (CGRP) son un novedoso tratamiento para prevenir la migraña crónica y la episódica de alta frecuencia.
Castaño-Amores, Celia +3 more
core +2 more sources
BMC Neurology, 2021 Background Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, is registered for migraine prevention. Compared to other conventional migraine prevention medicines (i.e.
C. K. Cullum +4 more
doaj +1 more source
Frontiers in Neurology, 2020 Background: German authorities reimburse migraine prevention with erenumab only in patients who previously did not have therapeutic success with at least five oral prophylactics or have contraindications to such.
Bianca Raffaelli +7 more
doaj +1 more source
The Journal of Headache and Pain, 2021 Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor.
Stewart J. Tepper +7 more
doaj +1 more source
The Journal of Headache and Pain, 2021 Background Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in randomized clinical trials. Large-
Andreas Straube +4 more
doaj +1 more source